Integrin αvβ3 targeting activity study of different retro-inverso sequences of RGD and their potentiality in the designing of tumor targeting peptides

Amino Acids

Volumn 47, Issue 12, 2015, Pages 2533-2539

  Liu, Yayuan ^a   Mei, Ling ^a   Yu, Qianwen ^a   Zhang, Qianyu ^a   Gao, Huile ^a   Zhang, Zhirong ^a   He, Qin ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Retro inverso; RGD peptide; Tandem peptide; Tumor targeting

Indexed keywords

ARGINYLARGINYLARGINYLARGINYLARGINYLARGINYLARGINYLARGINYLGLYCINE; ARGINYLARGINYLARGINYLARGINYLARGINYLARGINYLARGINYLARGINYLGLYCYLARGINYLGLYCYLASPARTIC ACID; ARGINYLARGINYLARGINYLARGINYLARGINYLARGINYLARGINYLARGINYLGLYCYLASPARTYLGLYCYLARGININE; ARGINYLGLYCYLASPARTIC ACID; PEPTIDE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; ANTINEOPLASTIC AGENT; ARGINYL-GLYCYL-ASPARTIC ACID; FLUORESCEIN ISOTHIOCYANATE; OLIGOPEPTIDE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; DRUG DELIVERY SYSTEM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MOUSE; NONHUMAN; ONCOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN STRUCTURE; PROTEIN TARGETING; RECEPTOR BINDING; RETRO INVERSO SEQUENCE; TUMOR TARGETING; TUMOR VASCULARIZATION; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG DESIGN; DRUG SCREENING; FLUORESCENCE MICROSCOPY; HELA CELL LINE; METABOLISM; NEOPLASM; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG DESIGN; FLUORESCEIN-5-ISOTHIOCYANATE; HELA CELLS; HUMANS; INTEGRIN ALPHAVBETA3; MICE; MICE, INBRED BALB C; MICROSCOPY, FLUORESCENCE; NEOPLASMS; OLIGOPEPTIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84946212271     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-015-2043-9     Document Type: Article

References (42)

1. Abraham T, Prenner EJ, Lewis RN, Mant CT, Keller S, Hodges RS, McElhaney RN (2014) Structure-activity relationships of the antimicrobial peptide gramicidin S and its analogs: aqueous solubility, self-association, conformation, antimicrobial activity and interaction with model lipid membranes. Biochim Biophys Acta 1838(5):1420-1429
2. Alberici L, Roth L, Sugahara KN, Agemy L, Kotamraju VR, Teesalu T, Bordignon C, Traversari C, Rizzardi G-P, Ruoslahti E (2013) De novo design of a tumor-penetrating peptide. Cancer Res 73(2):804-812
3. Barczyk M, Carracedo S, Gullberg D (2010) Integrins. Cell Tissue Res 339(1):269-280
4. Bernstein H-G, Dobrowolny H, Trübner K, Steiner J, Bogerts B, Hoffmann W (2015) Differential regional and cellular distribution of TFF3 peptide in the human brain. Amino Acids 47(5):1053-1063
5. Choi KY, Chung H, Min KH, Yoon HY, Kim K, Park JH, Kwon IC, Jeong SY (2010) Self-assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials 31(1):106-114
6. Contois LW, Akalu A, Caron JM, Tweedie E, Cretu A, Henderson T, Liaw L, Friesel R, Vary C, Brooks PC (2015) Inhibition of tumor-associated αvβ3 integrin regulates the angiogenic switch by enhancing expression of IGFBP-4 leading to reduced melanoma growth and angiogenesis in vivo. Angiogenesis 18(1):31-46
7. Dearling JL, Barnes JW, Panigrahy D, Zimmerman RE, Fahey F, Treves ST, Morrison MS, Kieran MW, Packard AB (2013) Specific uptake of 99m Tc-NC100692, an α v β 3-targeted imaging probe, in subcutaneous and orthotopic tumors. Nucl Med Biol 40(6):788-794
8. Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10(1):9-22
9. Gao H, Xiong Y, Zhang S, Yang Z, Cao S, Jiang X (2014) RGD and interleukin-13 peptide functionalized nanoparticles for enhanced glioblastoma cells and neovasculature dual targeting delivery and elevated tumor penetration. Mol Pharm 11(3):1042-1052
10. Gentilucci L, Cardillo G, Spampinato S, Tolomelli A, Squassabia F, De Marco R, Bedini A, Baiula M, Belvisi L, Civera M (2009) Antiangiogenic effect of dual/selective α5β1/αvβ3 integrin antagonists designed on partially modified retro-inverso cyclotetrapeptide mimetics. J Med Chem 53(1):106-118
11. Goel HL, Mercurio AM (2012) Enhancing integrin function by VEGF/neuropilin signaling: implications for tumor biology. Cell Adh Migr 6(6):554-560
12. Goodman M, Chorev M (1979) On the concept of linear modified retro-peptide structures. Acc Chem Res 12(1):1-7
13. Graf N, Bielenberg DR, Kolishetti N, Muus C, Banyard J, Farokhzad OC, Lippard SJ (2012) αVβ3 integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrug. ACS Nano 6(5):4530-4539
14. Guo Z, He B, Jin H, Zhang H, Dai W, Zhang L, Zhang H, Wang X, Wang J, Zhang X (2014) Targeting efficiency of RGD-modified nanocarriers with different ligand intervals in response to integrin αvβ3 clustering. Biomaterials 35(23):6106-6117
15. Kibria G, Hatakeyama H, Ohga N, Hida K, Harashima H (2011) Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. J Control Release 153(2):141-148
16. Kiugel M, Dijkgraaf I, Kytö V, Helin S, Liljenbäck H, Saanijoki T, Yim C-B, Oikonen V, Saukko P, Knuuti J (2014) Dimeric [68Ga] DOTA-RGD peptide targeting αvβ3 integrin reveals extracellular matrix alterations after myocardial infarction. Mol Imaging Biol 16(6):793-801
17. Leblanc R, Lee S, David M, Bordet J, Norman D, Patil R, Miller D, Sahay D, Ribeiro J, Clézardin P (2014) Interaction of platelet-derived autotaxin with tumor integrin αVβ3 controls metastasis of breast cancer cells to bone. Blood 124(20):3141-3150
18. Li Y, Lei Y, Wagner E, Xie C, Lu W, Zhu J, Shen J, Wang J, Liu M (2013) Potent retro-inverso D-peptide for simultaneous targeting of angiogenic blood vasculature and tumor cells. Bioconjug Chem 24(1):133-143
19. Lim J, Pellois J-P, Simanek EE (2010) A retro-inverso TAT-like peptide designed to deliver cysteamine to cells. Bioorg Med Chem Lett 20(21):6321-6323
20. Liu Y, Ran R, Chen J, Kuang Q, Tang J, Mei L, Zhang Q, Gao H, Zhang Z, He Q (2014) Paclitaxel loaded liposomes decorated with a multifunctional tandem peptide for glioma targeting. Biomaterials 35(17):4835-4847
21. Maeda H (2015) Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv Drug Deliv Rev. doi: 10.1016/j.addr.2015.01.002
22. Magnon C, Galaup A, Mullan B, Rouffiac V, Bidart J-M, Griscelli F, Opolon P, Perricaudet M (2005) Canstatin acts on endothelial and tumor cells via mitochondrial damage initiated through interaction with αvβ3 and αvβ5 integrins. Cancer Res 65(10):4353-4361
23. Mingozzi M, Manzoni L, Arosio D, Dal Corso A, Manzotti M, Innamorati F, Pignataro L, Lecis D, Delia D, Seneci P (2014) Synthesis and biological evaluation of dual action cyclo-RGD/SMAC mimetic conjugates targeting α v β 3/α v β 5 integrins and IAP proteins. Org Biomol Chem 12(20):3288-3302
24. Nie L, Wang S, Wang X, Rong P, Ma Y, Liu G, Huang P, Lu G, Chen X (2014) In vivo volumetric photoacoustic molecular angiography and therapeutic monitoring with targeted plasmonic nanostars. Small 10(8):1585-1593
25. Pang H-B, Braun GB, Friman T, Aza-Blanc P, Ruidiaz ME, Sugahara KN, Teesalu T, Ruoslahti E (2014) An endocytosis pathway initiated through neuropilin-1 and regulated by nutrient availability. Nat Commun. doi: 10.1038/ncomms5904
26. Qin Y, Chen H, Yuan W, Kuai R, Zhang Q, Xie F, Zhang L, Zhang Z, Liu J, He Q (2011) Liposome formulated with TAT-modified cholesterol for enhancing the brain delivery. Int J Pharm 419(1):85-95
27. Seguin L, Desgrosellier JS, Weis SM, Cheresh DA (2015) Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol. doi: 10.1016/j.tcb.2014.12.006
28. Shattil SJ, Kim C, Ginsberg MH (2010) The final steps of integrin activation: the end game. Nat Rev Mol Cell Biol 11(4):288-300
29. Staykova ST, Wesselinova DW, Vezenkov LT, Naydenova ED (2015) Synthesis and in vitro antitumor activity of new octapeptide analogs of somatostatin containing unnatural amino acids. Amino Acids 47(5):1007-1013
30. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Girard OM, Hanahan D, Mattrey RF, Ruoslahti E (2009) Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 16(6):510-520
31. Taylor EM, Otero DA, Banks WA, O'Brien JS (2000) Retro-inverso prosaptide peptides retain bioactivity, are stable In vivo, and are blood-brain barrier permeable. J Pharmacol Exp Ther 295(1):190-194
32. Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E (2009) C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci 106(38):16157-16162
33. Trabocchi A, Menchi G, Danieli E, Potenza D, Cini N, Bottoncetti A, Raspanti S, Pupi A, Guarna A (2010) Cyclic DGR-peptidomimetic containing a bicyclic reverse turn inducer as a selective αvβ5 integrin ligand. Amino Acids 38(1):329-337
34. Vachutinsky Y, Oba M, Miyata K, Hiki S, Kano MR, Nishiyama N, Koyama H, Miyazono K, Kataoka K (2011) Antiangiogenic gene therapy of experimental pancreatic tumor by sFlt-1 plasmid DNA carried by RGD-modified crosslinked polyplex micelles. J Control Release 149(1):51-57
35. Wang J, Lei Y, Xie C, Lu W, Wagner E, Xie Z, Gao J, Zhang X, Yan Z, Liu M (2014) Retro-inverso CendR peptide-mediated polyethyleneimine for intracranial glioblastoma-targeting gene therapy. Bioconjug Chem 25(2):414-423
36. Wermuth J, Goodman S, Jonczyk A, Kessler H (1997) Stereoisomerism and biological activity of the selective and superactive αvβ3 integrin inhibitor cyclo (-RGDfV-) and its retro-inverso peptide. J Am Chem Soc 119(6):1328-1335
37. Winograd-Katz SE, Fässler R, Geiger B, Legate KR (2014) The integrin adhesome: from genes and proteins to human disease. Nat Rev Mol Cell Biol 15(4):273-288
38. Yan H, Wang L, Wang J, Weng X, Lei H, Wang X, Jiang L, Zhu J, Lu W, Wei X (2011) Two-order targeted brain tumor imaging by using an optical/paramagnetic nanoprobe across the blood brain barrier. ACS Nano 6(1):410-420
39. Yang G, Sun H, Kong Y, Hou G, Han J (2014) Diversity of RGD radiotracers in monitoring antiangiogenesis of flavopiridol and paclitaxel in ovarian cancer xenograft-bearing mice. Nucl Med Biol 41(10):856-862
40. YoungáChoi K, HyunáMin K, HeeáNa J, ChanáKwon I, YoungáJeong S (2009) Self-assembled hyaluronic acid nanoparticles as a potential drug carrier for cancer therapy: synthesis, characterization, and in vivo biodistribution. J Mater Chem 19(24):4102-4107
41. Zhang Q, Tang J, Fu L, Ran R, Liu Y, Yuan M, He Q (2013) A pH-responsive α-helical cell penetrating peptide-mediated liposomal delivery system. Biomaterials 34(32):7980-7993
42. Zheng Y, Ji S, Czerwinski A, Valenzuela F, Pennington M, Liu S (2014) FITC-conjugated cyclic RGD peptides as fluorescent probes for staining integrin αvβ3/αvβ5 in tumor tissues. Bioconjug Chem 25(11):1925-1941